Merck Is in Advanced Talks to Buy Cancer Biotech Seagen

by | Jul 6, 2022 | Business

Merck & Co. is in advanced talks to acquire Seagen and is aiming to agree on a purchase of the cancer biotech in the next few weeks, according to people familiar with the matter, in a deal that could be worth roughly $40 billion or more.The companies are discussing a price for Seagen above $200 a share and are seeking to seal a deal on or before the announcement of Merck’s quarterly earnings, set for July 28, the people said. Seagen’s stock closed at $175.13 on Wednesday.

Article Attribution | Read More at Article Source

Share This